NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Forecast, Price & News $1.46 -0.03 (-2.01%) (As of 12:08 PM ET) Add Compare Share Share Today's Range$1.44▼$1.4950-Day Range$1.49▼$1.8752-Week Range$1.12▼$5.64Volume3,485 shsAverage Volume32,286 shsMarket Capitalization$6.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Aileron Therapeutics (NASDAQ:ALRN) StockAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Read More ALRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALRN Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short InterestApril 4, 2023 | finance.yahoo.comBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' NowSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsMarch 22, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN)March 14, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 3, 2023 | msn.comLooking Into Aileron Therapeutics's Recent Short InterestFebruary 23, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)February 22, 2023 | finance.yahoo.comCancer drugmaker down to 3 employees after trial failureSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsFebruary 21, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%February 21, 2023 | seekingalpha.comAileron off 38% on plans to explore sale after setback for cancer candidateFebruary 21, 2023 | finance.yahoo.comAileron Therapeutics Shelves Development On Chemoprotection Agent, Shares FallFebruary 21, 2023 | markets.businessinsider.comAileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924February 21, 2023 | marketwatch.comAileron Therapeutics Shares Slide to New Low on Lead Drug Failure >ALRNFebruary 21, 2023 | marketwatch.comAileron Exploring Options After ALRN-6924 Study Failure >ALRNJanuary 17, 2023 | reuters.comalrn.a - | Stock Price & Latest News | ReutersDecember 29, 2022 | msn.comWhat Makes Aileron Therapeutics, Inc. (ALRN) a New Buy StockNovember 30, 2022 | finance.yahoo.comAileron Therapeutics Regains Compliance with Nasdaq Listing RequirementsNovember 24, 2022 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowNovember 10, 2022 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Announces a 1-for-20 Reverse Stock SplitNovember 10, 2022 | finance.yahoo.comAileron Therapeutics Announces a 1-for-20 Reverse Stock SplitNovember 4, 2022 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the UpgradeNovember 1, 2022 | technews.tmcnet.comAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 1, 2022 | finance.yahoo.comAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsOctober 26, 2022 | finance.yahoo.comAileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International ConferenceSeptember 30, 2022 | finance.yahoo.comAileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022September 22, 2022 | finance.yahoo.comAileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare ConferenceSee More Headlines Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALRN Company Calendar Last Earnings8/11/2023Today9/26/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-96.27% Return on Assets-81.90% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.36Miscellaneous Outstanding Shares4,540,000Free Float4,382,000Market Cap$6.76 million OptionableNot Optionable Beta2.13 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Manuel C. Aivado M.D. (Age 53)Ph.D., Pres, CEO & Director Comp: $700.57kDr. D. Allen Annis Ph.D. (Age 50)Sr. VP of Research Comp: $422.01kMs. Susan L. Drexler CPA (Age 53)M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer Key CompetitorsCervoMedNASDAQ:CRVOKintara TherapeuticsNASDAQ:KTRATenax TherapeuticsNASDAQ:TENXAthersysNASDAQ:ATHXAdamis PharmaceuticalsNASDAQ:ADMPView All Competitors ALRN Stock - Frequently Asked Questions How have ALRN shares performed in 2023? Aileron Therapeutics' stock was trading at $2.37 at the beginning of 2023. Since then, ALRN shares have decreased by 37.1% and is now trading at $1.49. View the best growth stocks for 2023 here. Are investors shorting Aileron Therapeutics? Aileron Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 6,300 shares, an increase of 40.0% from the August 15th total of 4,500 shares. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.2% of the shares of the company are sold short. View Aileron Therapeutics' Short Interest. When is Aileron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our ALRN earnings forecast. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its earnings results on Friday, August, 11th. The company reported ($0.39) EPS for the quarter. When did Aileron Therapeutics' stock split? Shares of Aileron Therapeutics reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV). When did Aileron Therapeutics IPO? (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What is Aileron Therapeutics' stock symbol? Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN." How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aileron Therapeutics' stock price today? One share of ALRN stock can currently be purchased for approximately $1.49. How much money does Aileron Therapeutics make? Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $6.76 million. How can I contact Aileron Therapeutics? Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com. This page (NASDAQ:ALRN) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.